

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Koker, Daniel E. K. Ballard
(Use as many sheets as necessary)				Attorney Docket Number	15270J-004743US
Sheet	1	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1094	American Type Culture Collection (ATCC) Search Results for "IKTR, 1ETZ, 1JRH", http://www.atcc.org/ , pp. 1-3, 02/22/2007.	<input type="checkbox"/>
	1091	CLARK et al., <i>Chemical Immunology Antibody Engineering IgG Effector Mechanisms</i> , 65:88-110 (1997).	<input type="checkbox"/>
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1988).	<input type="checkbox"/>
	931	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , page 98 (1988).	<input type="checkbox"/>
	1086	HOLMES et al., "Long-term Effects of A β ₄₂ Immunisation in Alzheimer's Disease: Follow-up of a Randomised, Placebo-controlled Phase I Trial," <i>Lancet</i> , 372: 216-223 (2008).	<input type="checkbox"/>
	1090	HOPP et al., "Prediction of protein antigenic determinants from amino acid sequences," <i>Proc. Natl. Acad. Sci. USA</i> 78:3824-3828 (1981).	<input type="checkbox"/>
	1092	HUSSAIN et al., "Selective Increases in Antibody Isotopes and Immunoglobulin G Subclass Responses to Secreted Antigens in Tuberculosis Patients and Healthy Household Contacts of the Patients," <i>Clinical and Diagnostic Laboratory Immunology</i> , 2(6): 726-732 (1995).	<input type="checkbox"/>
	1087	HYSLOP et al., "Will Anti-amyloid Therapies Work For Alzheimer's Disease?," <i>Lancet</i> , 372:180-182 (2008).	<input type="checkbox"/>
	1088	NASHAR et al., "Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes," <i>Vaccine</i> , 11(2):235-40 (1993), abstract only.	<input type="checkbox"/>
	1095	Putative CDR determination for SEQ Id NOs: 2 and 4 (pp. 1-2), 06/10/2004.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/724,319
		Filing Date	November 27, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Kelker, Daniel E. K. Ballard
		Attorney Docket Number	15270J-004743US
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1089	ROLPH et al., "Recombinant viruses as vaccines and immunological tools," <u>Immunity to Infection</u> , 9:517-521 (1997).	<input type="checkbox"/>
	1093	STAUNTON et al., "Primary structures of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families," <u>Cell</u> 52(6):925-33 (1988), abstract only.	<input type="checkbox"/>

Examiner Signature	/Kimberly Ballard/	Date Considered	03/30/2009
--------------------	--------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.